Paris, France

Nassima Messal


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Nassima Messal

Introduction: Nassima Messal, a talented inventor based in Paris, France, has made significant contributions to the field of medical research. With a focus on treating inflammatory bowel diseases, her innovative work is paving the way for new therapeutic options.

Latest Patents: Nassima holds a notable patent titled "Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor." This invention pertains to methods and pharmaceutical compositions aimed at treating inflammatory bowel diseases. The method involves administering a therapeutically effective amount of at least one OX1R agonist to a subject in need, providing a potential new avenue for those suffering from this condition.

Career Highlights: Throughout her career, Nassima has been affiliated with prestigious organizations such as the Institut National de la Santé et de la Recherche Médicale and Université Paris Diderot—Paris 7. Her work at these renowned institutions has allowed her to delve deeply into research, facilitating advancements in medical science.

Collaborations: During her professional journey, Nassima has collaborated with accomplished colleagues including Alain Couvineau and Thierry Voisin. These partnerships have not only enriched her work but have also contributed significantly to the scientific community's collective knowledge regarding inflammatory bowel diseases.

Conclusion: Nassima Messal's innovative contributions in the field of medical research underscore her dedication to improving the lives of those affected by inflammatory bowel diseases. Her patent reflects a forward-thinking approach and highlights the potential for new therapeutic strategies, positioning her as a noteworthy inventor in the realm of medical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…